Management of hepatitis C: Current and future perspectives

Journal of Hepatology, Supplement

Volumn 31, Issue 1, 1999, Pages 264-268

  Hoofnagle, Jay H ^a,b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cirrhosis; Consensus conferences; Controlled trials; Hepatitis C; Hepatitis C virus; Interferon; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; RIBAVIRIN; VIRUS RNA;

CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; DRUG RESPONSE; ERADICATION THERAPY; EVIDENCE BASED MEDICINE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIDE EFFECT; VIRUS TYPING;

EID: 0033404709     PISSN: 01695185     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(99)80414-0     Document Type: Conference Paper

References (9)

1. Choo Q-L, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a bloodborne non-A, non-B viral hepatitis genome. Science 1989: 244: 359-362.
2. Kuo G, Choo Q-L, Alter HJ, Gitnick GL, Redeker AG, Purcell H et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B antibodies. Science 1989:244: 362-364.
3. National Institutes of Health Consensus Development Conference Panel. Management of hepatitis C. Hepatology 1997: 26 (Suppl 1): 2S-16S.
4. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK. et al. for the Hepatitis Interventional Therapy Group. Interferon alpha 2-b alone or in combination with ribavi-rin as initial treatment for chronic hepatitis C. N Engl J Med 1998: 339: 1485-1492.
5. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C et al. for the International Hepatitis Interventional Therapy Group. N Engl J Med 1998: 339: 1493-1499.
6. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G et al. for the International Hepatitis Interventional Therapy Group. Randomised trial of interferon alb plus ribavirin for 48 weeks or for 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998: 352: 1426-1432.
7. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR (Morb Mort Wkly Rep) 1998: 47 (No. RR-19): 1-39.
8. Neumann AU, Lam NP, Dahari H,.Gretch DR, Wiley TE, Layden TJ et al. Hepatitis C viral dynamics in vj'vo and the antiviral efficacy of interferon-a therapy. Science 1998: 282: 103-109.
9. Hu Z-X, Hoffman J, Patel I, Joubert P. Single-dose, safety-tolerability and pharmacokinetic-pharmacodynamics following administration of ascending subcutaneous doses of pegylated-interferon and interferon alpha-2a to healthy subjects. Hepatology 1998: 28: 708A [abstract].